StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $1.52 | $1.72 | +13.16% | 0.5M |
| 05-14 | $1.73 | $1.74 | +0.58% | 0.5M |
| 05-15 | $1.57 | $1.48 | -5.73% | 0.6M |
| 05-18 | $1.48 | $1.51 | +2.03% | 1.1M |
| 05-19 | $1.55 | $1.55 | +0.00% | 0.5M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 | Q3 2025 2025-09-30 | Annual 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-6.06M | $-4.03M | $-1.80M | $-9.59M |
Net Income | $-6.00M | $-2.22M | $-1.79M | $-9.47M |
EPS (Diluted) | $-0.31 | $-0.22 | $-0.10 | $-0.63 |
Total Assets | $10.22M | $12.27M | $8.36M | $8.82M |
Total Liabilities | $1.10M | $1.20M | $1.20M | $1.30M |
Cash & Equivalents | $3.21M | $5.15M | $1.13M | $1.56M |
Free Cash Flow OCF − CapEx | $-5.66M | $-3.73M | $-1.68M | $-8.54M |
Shares Outstanding | 21.65M | 21.60M | 17.56M | 16.61M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.